Avastin Breast Cancer Approval Memo Comes Back To Haunt FDA’s Pazdur

Reflected in the regulatory struggle over Avastin’s (bevacizumab) metastatic breast cancer claim is the uncertainty underlying drug approval decisions for FDA and sponsors, laying bare the sometimes tenuous evidence with which the agency has to work.